Compare SAFT & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAFT | OPK |
|---|---|---|
| Founded | 1979 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 1995 |
| Metric | SAFT | OPK |
|---|---|---|
| Price | $75.80 | $1.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $2.28 |
| AVG Volume (30 Days) | 90.0K | ★ 3.7M |
| Earning Date | 11-03-2025 | 10-29-2025 |
| Dividend Yield | ★ 4.72% | N/A |
| EPS Growth | ★ 15.78 | N/A |
| EPS | ★ 5.87 | N/A |
| Revenue | ★ $1,231,116,000.00 | $642,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.27 | ★ N/A |
| Revenue Growth | ★ 12.77 | N/A |
| 52 Week Low | $67.04 | $1.11 |
| 52 Week High | $84.20 | $2.04 |
| Indicator | SAFT | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 41.85 | 41.22 |
| Support Level | $78.10 | $1.29 |
| Resistance Level | $79.26 | $1.34 |
| Average True Range (ATR) | 1.45 | 0.05 |
| MACD | -0.39 | -0.00 |
| Stochastic Oscillator | 0.42 | 17.74 |
Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. It operates in the business segment of Property and casualty insurance operations.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.